Loading...
Market
How will Amgen's stock price change by end of Q2 2025 post-Bkemv launch?
4
Resolution / Starting Odds
Increase over 20% • 25%
Increase 10-20% • 25%
Decrease 10-20% • 25%
Decrease over 20% • 25%
Stock market data
Story
FDA Approves $AMGN's Bkemv, First Biosimilar to $AZN's Soliris
May 28, 2024, 10:11 PM
The U.S. Food and Drug Administration (FDA) has approved Amgen Inc's Bkemv, the first biosimilar to AstraZeneca's Soliris. This biosimilar is designed to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis and patients with atypical hemolytic uremic syndrome (aHUS) to inhibit hemolysis. The approval marks a significant milestone as Bkemv is the first interchangeable biosimilar for these rare diseases. The approval is a notable development for $AMGN and $AZN.
View original story
Similar markets
Stock price increases by over 20% • 33%
Stock price increases by 10-20% • 33%
Stock price increases by less than 10% • 34%
Increase by more than 5% • 25%
Increase by less than 5% • 25%
Decrease by less than 5% • 25%
Decrease by more than 5% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Stock price increases • 33%
Stock price decreases • 33%
Stock price remains stable • 34%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Decrease by more than 10% • 33%
No significant change • 33%
Increase by more than 10% • 33%
Increase over 200% • 25%
Increase 100-200% • 25%
Increase up to 100% • 25%
Decrease or no change • 25%
Yes • 50%
No • 50%
10-20% increase • 25%
21-50% increase • 25%
51-100% increase • 25%
more than 100% increase • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%